4张建国----早期乳腺癌助化疗中文4张建国----早期乳腺癌辅助化疗中文4张建国----早期乳腺癌辅助化疗中文4张建国----早期乳腺癌辅助化疗中文.ppt

下载文档 降价啦

9
0
约 64页
2017-03-18 发布于贵州
举报
版权申诉
保障服务

4张建国----早期乳腺癌助化疗中文4张建国----早期乳腺癌辅助化疗中文4张建国----早期乳腺癌辅助化疗中文4张建国----早期乳腺癌辅助化疗中文.ppt

1、本文档共64页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

4张建国----早期乳腺癌助化疗中文4张建国----早期乳腺癌辅助化疗中文4张建国----早期乳腺癌辅助化疗中文4张建国----早期乳腺癌辅助化疗中文

* USO 9735 是III期临床，研究TC方案的疗效及安全性目的在于比较非蒽环类方案与标准蒽环类方案治疗可手术乳腺癌 is a phase III study designed to evaluate the efficacy and safety of docetaxel–cyclophosphamide. The goal is to compare a non-anthracycline containing regimen with a standard anthracycline combination for the treatment of patients with operable breast cancer. * * * * * * * * * * * * * Her Neg as of 8 ‘05 * * * * * * NSABP B-38 Disease-Free Survival 0 1 2 3 4 5 0.0 0.2 0.4 0.6 0.8 1.0 Years since Randomization Disease-Free Survival Treat N Events P-value* (vs AC?PG) TAC 1610 327 0.410 AC?P 1618 294 0.388 AC?PG 1613 320 # at risk 1610 1532 1424 1331 1217 719 1618 1554 1452 1348 1240 754 1613 1533 1453 1350 1244 730 * Stratified log-rank test adjusting for randomization factors NSABP B-38 Overall Survival 0 1 2 3 4 5 0.0 0.2 0.4 0.6 0.8 1.0 Years since Randomization Overall Survival Treat N Deaths P-value* (vs AC?PG) TAC 1617 185 0.167 AC?P 1624 188 0.133 AC?PG 1618 167 # at risk 1617 1588 1539 1487 1433 913 1624 1602 1557 1504 1439 938 1618 1596 1557 1514 1446 928 * Stratified log-rank test adjusting for randomization factors NSABP B-38AML/MDS (N) AC?P (1618) TAC (1610) 8 AC?PG (1613) 11 5 P=0.46 Conclusion Addition of G to DD AC?P did not improve outcomes No significant differences in efficacy between DD AC?P and TAC Toxicity profiles differed with more neuropathy and anemia on DD arms and more diarrhea and febrile neutropenia on TAC Exploratory analyses: No outcome differences with or without erythropoietin These results are in node positive BC (Applicable to node negative?) Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab (HER TC) in HER2 Positive Early Stage Breast Cancer Patients Steve Jones, MD1,2; Rufus Co